Dr. Hazel Szeto's discovery of a first-in-class compound that had mitochondrial therapeutic potential is now a U.S. Food and Drug Administration-approved drug.
Weill Cornell Medicine’s Ninth Annual Dean’s Symposium on Innovation and Entrepreneurship celebrated and fostered the entrepreneurial spirit on Nov. 17 at Weill Cornell's Griffis Faculty Club.
A rare gene mutation that delays Alzheimer’s disease does so by damping inflammatory signaling in brain-resident immune cells, according to a preclinical study led by investigators at Weill Cornell Medicine.
A non-opioid designer molecule for treating chronic neuropathic pain by calming hyperactive pain-sensing neurons in the peripheral nervous system has had promising results in a preclinical study.
An experimental contraceptive drug candidate developed by Weill Cornell Medicine investigators temporarily stops sperm in their tracks and prevents pregnancies in preclinical models.
